TLD-1, a Novel Liposomal Doxorubicin, in Patients With Advanced Solid Tumors
Status:
Recruiting
Trial end date:
2023-10-01
Target enrollment:
Participant gender:
Summary
TLD-1 is a novel liposomal formulation of doxorubicin (PEG surface) that compared favorably
to conventional liposomal formulations of doxorubicin including Caelyx® in preclinical in
vivo models. Particle features including size, charge distribution, lipid composition and
drug release add up to a considerably altered particle behavior compared to Caelyx®,
potentially explaining the lack of hand-foot-syndrome in respective animal models.
Preclinical evaluation confirmed TLD-1 to be a promising new and innovative formulation of
doxorubicin with promising activity and good tolerability.